Afatinib as first-line treatment in Asian patients with EGFR mutation-positive NSCLC: A narrative review of real-world evidence

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small-cell lung cancer (NSCLC). EGFR mutations are relatively common in Asian patients with NSCLC, and there is an increas...

Full description

Saved in:
Bibliographic Details
Main Authors: Lu, Shun, Shih, Jin-Yuan, Jang, Tae-Won, Liam, Chong-Kin, Yu, Yongfeng
Format: Article
Published: Springer 2021
Subjects:
Online Access:http://eprints.um.edu.my/26835/
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Malaya